Drug Type Monoclonal antibody |
Synonyms ADA-011 |
Target |
Action inhibitors |
Mechanism LILRB inhibitors(Inhibitory leukocyte immunoglobulin like receptors inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 15 Nov 2022 |